~~<i id='55EED55D24'><strike id='55EED55D24'><tt id='55EED55D24'><pre id='55EED55D24'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

hotspot

fashion

author：comprehensive 2025-09-06 08:39:42 - browse：1836

Michel Pairet -- health business coverage from STAT — Michel Pairet Courtesy Boehringer Ingelheim

LONDON — At an event here last week, the German pharmaceutical firm Boehringer Ingelheim outlined the projects in its pipeline.

There was obesity and liver disease, and computational biology and oncology. Then respiratory and inflammatory diseases. And don’t forget mental illness and retinal health. Oh, it was also the day the company launched another Humira biosimilar.

In other words, there was a whole lot for the company to discuss as it works to promote its breadth and build partnerships with academic researchers and other companies.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： United colonoscopy coverage change 'may cost lives,' doctors say
Next article： Nurses recount patients attacks

leisure time

explore

entertainment

hotspot

knowledge

focus

Editor’snote:Arecordingoftheeventisembeddedbelow.SeveralbiosimilarversionsofHumira,whichforyearshasb

WSS

Leading voice in opioid treatment defends methadone clinic system

Unmasking the 'centricity' illusion in clinical trials

J&J reports mixed data on next

Beyond aggravation: Constipation is an American epidemic

Richard Slayman had a rejection episode of his pig kidney before leaving hospital

Louisiana bill approved classifying abortion pills as controlled substances

hotspot

fashion

leisure time

Activists slam private health insurers over coverage restrictions

AstraZeneca to buy developer of next

Guidelines to prevent youth baseball injuries need more muscle

Colonoscopy prep: Liquid

New air purifier tech could be key to improving indoor air quality

New research sheds light on how often breast cancer is overdiagnosed

Walensky prepares to leave CDC — and Congress — behind

Stroke rates rising, especially in working

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Readout Newsletter: Geron, Novo Nordisk, WuXi updates

explore

Orchard's therapy for neuron disease in children wins FDA approval

U.S. death rates show how politics are affecting public health

Ozempic cut risk of death in diabetes patients with chronic kidney disease

Gene editing the human germline: What are the risks?

Some medical students still think black patients feel less pain

Bird flu makes raw milk dangerous to consume, mouse study finds

entertainment

hotspot

knowledge

focus